Intellectual Property

Proprietary Preclinical Models

CXR Biosciences is focused on developing new models for assessing efficacy, ADME, and toxicity that are more rapid, more informative, and more relevant to man, than existing approaches. These models have been designed to address the limitations of current techniques, and accelerate the process of drug development in an informed manner.

CXR Biosciences has developed preclinical models to rapidly determine in vivo the role of hepatic cytochrome P450s in drug disposition (the HRN mouse), to non-invasively determine the in vivo mechanisms of toxicity (toxicity reporter models), and to non-invasively determine the cellular mechanism of action and efficacy of anti cancer agents in vivo (Smart Xenografts).

We are currently prosecuting 8 patent families that protect this range of technologies.